PharmaCielo Announces 2025 Q3 Results, AGM Details

Executive Summary

• PharmaCielo reported nine‑month revenue of $1.818 M, down from $3.240 M a year earlier.
• Adjusted EBITDA swung to a loss of $293 K (previously a loss of $2.295 M), indicating improved operational discipline.
• Net loss for the period narrowed to $2.279 M versus $6.721 M in the prior year, or $(0.01) per share versus $(0.04).

Key Details

• Revenue: $1,818,000 (nine months ended Dec 31 2025) vs. $3,240,000 (same period 2024).
• Adjusted EBITDA (Loss): $293,000 vs. $(2,295,000) in 2024.
• Net Loss: $(2,279,000) vs. $(6,721,000) a year earlier.
• Net Loss per Share: $(0.01) vs. $(0.04) a year earlier.
• Management highlighted “rightsizing the organization,” improved production efficiencies in Colombia, and a focus on higher‑margin export opportunities.
• Upcoming Annual General Meeting scheduled for April 2 2026; record date set for February 23 2026.

Notable Quotes

“The third quarter marked an important turning point for PharmaCielo… The significant improvement in Adjusted EBITDA demonstrates the operational discipline and cost controls implemented over the past year.” – Marc Lustig, Chairman & CEO

All figures are presented in Canadian dollars unless otherwise noted.